{
    "ticker": "KPRX",
    "name": "Kiora Pharmaceuticals, Inc.",
    "description": "Kiora Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of ocular diseases. Founded in 2017, Kiora is dedicated to addressing significant unmet medical needs in the eye care market. The company is particularly known for its proprietary product candidates designed to improve patient outcomes in conditions such as glaucoma, dry eye, and retinal diseases. Kiora's flagship product, KIO-301, is a novel therapeutic aimed at enhancing ocular drug delivery and improving the safety and efficacy of existing treatments. The company employs advanced technologies to formulate and deliver its therapies, fostering partnerships with leading research institutions and industry players. Kiora Pharmaceuticals is committed to advancing the science of eye care through clinical research and innovation, striving to provide patients with effective treatment options that enhance their quality of life. With a robust pipeline and a strong focus on research and development, Kiora aims to become a leader in the ocular therapeutics space.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2017",
    "website": "https://www.kiorapharma.com",
    "ceo": "David A. H. E. H. S. J. H. Decker",
    "social_media": {
        "twitter": "https://twitter.com/KioraPharma",
        "linkedin": "https://www.linkedin.com/company/kiora-pharmaceuticals/"
    },
    "investor_relations": "https://ir.kiorapharma.com",
    "key_executives": [
        {
            "name": "David A. H. E. H. S. J. H. Decker",
            "position": "CEO"
        },
        {
            "name": "Thomas H. M. Decker",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "KIO-301"
            ]
        }
    ],
    "seo": {
        "meta_title": "Kiora Pharmaceuticals, Inc. | Innovative Ocular Therapies",
        "meta_description": "Explore Kiora Pharmaceuticals, Inc., a leading biopharmaceutical company focused on developing innovative therapies for ocular diseases. Learn about our pipeline and commitment to eye care.",
        "keywords": [
            "Kiora Pharmaceuticals",
            "Ocular Therapies",
            "Biopharmaceuticals",
            "Eye Care",
            "Glaucoma Treatment",
            "Dry Eye Therapy"
        ]
    },
    "faq": [
        {
            "question": "What is Kiora Pharmaceuticals known for?",
            "answer": "Kiora Pharmaceuticals is known for developing innovative therapies for the treatment of ocular diseases."
        },
        {
            "question": "Who is the CEO of Kiora Pharmaceuticals?",
            "answer": "David A. H. E. H. S. J. H. Decker is the CEO of Kiora Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Kiora Pharmaceuticals headquartered?",
            "answer": "Kiora Pharmaceuticals is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is Kiora's main product?",
            "answer": "Kiora's main product is KIO-301, aimed at enhancing ocular drug delivery."
        },
        {
            "question": "When was Kiora Pharmaceuticals founded?",
            "answer": "Kiora Pharmaceuticals was founded in 2017."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "VRTX"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "AMZN",
        "MSFT"
    ]
}